Abatacept in the treatment of rheumatoid arthritis

Maya H Buch, Edward M Vital, Paul Emery

Research output: Contribution to journalReview articlepeer-review


T-cell biology has regained importance in the pathogenesis of rheumatoid arthritis. Despite the significant improvements associated with the introduction of tumor necrosis factor-alpha blockade, reasonable proportions of failures and suboptimal responses have been reported, necessitating a search for alternative targeted therapies. This has included drug therapy designed to interrupt T-cell activation via the co-stimulation pathway. Abatacept is a recombinant fusion protein that blocks the co-stimulatory signal mediated by the CD28-CD80/86 pathway, which is required for T-cell activation. Several clinical trials have confirmed the safety and efficacy of this drug in the treatment of rheumatoid arthritis. This review summarizes the clinical data supporting this line of treatment and considers the safety and efficacy data from phase II and III trials.

Original languageEnglish
Article numberS5
Number of pages10
JournalArthritis Research & Therapy
Issue numberSuppl 1
Publication statusPublished - 2008


  • Abatacept
  • Antirheumatic Agents/therapeutic use
  • Arthritis, Rheumatoid/drug therapy
  • Humans
  • Immunoconjugates/therapeutic use
  • T-Lymphocytes/immunology


Dive into the research topics of 'Abatacept in the treatment of rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this